PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global
specialty-driven biopharmaceutical company, announced today the appointment of
Keira Driansky as EVP, President of North America, effective May 13, 2024. She
will serve on the Executive Leadership Team (ELT) and report directly to Ipsen's
Chief Executive Officer (CEO), David Loew.
"We are thrilled to welcome Keira to Ipsen as our new President of North America
as she brings extensive experience in the life sciences industry and a proven
track record of leadership to our team," said David Loew, CEO Ipsen. "As we
continue to navigate the complexities of the pharmaceutical landscape, Keira's
strategic vision will be instrumental in guiding our company toward a future of
bringing groundbreaking medicines and enhanced outcomes to patients."
Keira will be joining Ipsen from AstraZeneca, where she spent the last 13 years
leading teams across the US, Europe and global functions. Most recently Keira
served as Country President of AstraZeneca for Belgium and Luxembourg, where she
oversaw 14 launches across various therapeutic areas, leading AZ to become the
fastest-growing pharma company in Belgium. Previously, she served as VP, Global
Commercial Head for Tagrisso across more than 90 countries. She also spent more
than five years in AZ's US Oncology business leading multiple sales and
marketing teams through six launches. ?
A former science researcher, Keira brings broad experience across the healthcare
industry, from commercial leadership to healthcare investing and business
development. She received her MBA from Harvard Business School and an MPhil in
Bioscience Enterprise from the University of Cambridge. Keira also conducted
breast cancer epidemiology research at the University of Oxford as a Marshall
Scholar and conducted biochemistry research at Yale under a Howard Hughes
Medical Fellowship.
"I'm excited to join the talented and established team at Ipsen at this time of
dynamic growth, with four innovative launches across therapeutic areas,
including the latest in first-line pancreatic cancer," said Keira Driansky. "I
look forward to partnering with Ipsen's employees, customers, and stakeholders
across the healthcare ecosystem to deliver breakthrough solutions for some of
the most pressing global health challenges of our time."
Stewart Campbell, who as Ipsen's President of North America for three years led
the acceleration of Ipsen's growth, will leave Ipsen to pursue other
opportunities.
ENDS
About Ipsen
We are a global biopharmaceutical company with a focus on bringing
transformative medicines to patients in three therapeutic areas: Oncology, Rare
Disease and Neuroscience.
Our pipeline is fueled by external innovation and supported by nearly 100 years
of development experience and global hubs in the U.S., France and the U.K. Our
teams in more than 40 countries and our partnerships around the world enable us
to bring medicines to patients in more than 80 countries.
Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored
Level I American Depositary Receipt program (ADR: IPSEY). For more information,
visit ipsen.com.
Ipsen contacts
Investors
* Craig Marks | +44 (0)7584 349 193 | craig.marks@ipsen.com
* Nicolas Bogler | +33 6 52 19 98 92 | nicolas.bogler@ipsen.com
Media
* Amy Wolf | +41 79 576 07 23 | amy.wolf@ipsen.com
* Elizabeth Kalina | +1 857 331 0060| elizabeth.kalina@ipsen.com
Disclaimers and/or Forward-Looking Statements
The forward-looking statements, objectives and targets contained herein are
based on Ipsen's management strategy, current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may cause
actual results, performance or events to differ materially from those
anticipated herein. All of the above risks could affect Ipsen's future ability
to achieve its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available today. Use of the
words 'believes', 'anticipates' and 'expects' and similar expressions are
intended to identify forward-looking statements, including Ipsen's expectations
regarding future events, including regulatory filings and determinations.
Moreover, the targets described in this document were prepared without taking
into account external-growth assumptions and potential future acquisitions,
which may alter these parameters. These objectives are based on data and
assumptions regarded as reasonable by Ipsen. These targets depend on conditions
or facts likely to happen in the future, and not exclusively on historical data.
Actual results may depart significantly from these targets given the occurrence
of certain risks and uncertainties, notably the fact that a promising medicine
in early development phase or clinical trial may end up never being launched on
the market or reaching its commercial targets, notably for regulatory or
competition reasons. Ipsen must face or might face competition from generic
medicine that might translate into a loss of market share. Furthermore, the
research and development process involves several stages each of which involves
the substantial risk that Ipsen may fail to achieve its objectives and be forced
to abandon its efforts with regards to a medicine in which it has invested
significant sums. Therefore, Ipsen cannot be certain that favorable results
obtained during preclinical trials will be confirmed subsequently during
clinical trials, or that the results of clinical trials will be sufficient to
demonstrate the safe and effective nature of the medicine concerned. There can
be no guarantees a medicine will receive the necessary regulatory approvals or
that the medicine will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the forward-looking
statements. Other risks and uncertainties include but are not limited to,
general industry conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and healthcare legislation; global trends
toward healthcare cost containment; technological advances, new medicine and
patents attained by competitors; challenges inherent in new-medicine
development, including obtaining regulatory approval; Ipsen's ability to
accurately predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of Ipsen's patents and other protections for
innovative medicines; and the exposure to litigation, including patent
litigation, and/or regulatory actions. Ipsen also depends on third parties to
develop and market some of its medicines which could potentially generate
substantial royalties; these partners could behave in such ways which could
cause damage to Ipsen's activities and financial results. Ipsen cannot be
certain that its partners will fulfil their obligations. It might be unable to
obtain any benefit from those agreements. A default by any of Ipsen's partners
could generate lower revenues than expected. Such situations could have a
negative impact on Ipsen's business, financial position or performance. Ipsen
expressly disclaims any obligation or undertaking to update or revise any
forward-looking statements, targets or estimates contained in this press release
to reflect any change in events, conditions, assumptions or circumstances on
which any such statements are based, unless so required by applicable law.
Ipsen's business is subject to the risk factors outlined in its registration
documents filed with the French Autorité des Marchés Financiers. The risks and
uncertainties set out are not exhaustive and the reader is advised to refer to
Ipsen's latest Universal Registration Document, available on ipsen.com
(https://www.globenewswire.com/Tracker?data=cRbeTYiLm_i554EQ7ITgGkjFSkEO7CuADsdG
INJYRhuLZP1b2RRGQKaNMQhqDBefwdyOcUcRf2VYKHI9RWUEWA==).
Â